Navitoclax is an orally bioavailable small molecule inhibitor of Bcl-2 family proteins. It has been used in trials studying the treatment and basic science of Solid Tumors, Non-Hodgkin's Lymphoma, EGFR Activating Mutation, Chronic Lymphoid Leukemia, and Hematological Malignancies, among others. Reference standards of Navitoclax API,and its pharmacopeial, non pharmacopeial impurities, and stable isotopes are listed below.
Navitoclax
Catalogue No.:PA 14 82000
CAS :
Molecular Formula : C47H55ClF3N5O6S3
Molecular Weight : 974.61
I accept terms and conditions
Message sent successfully!! We will get back to you shortly ....